Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

104.64USD
19 Jan 2018
Change (% chg)

$0.83 (+0.80%)
Prev Close
$103.81
Open
$104.46
Day's High
$104.85
Day's Low
$103.55
Volume
1,888,046
Avg. Vol
1,581,597
52-wk High
$104.85
52-wk Low
$59.27

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Abbvie's Upadacitinib Granted Breakthrough Therapy Designation From FDA

* ABBVIE'S UPADACITINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

08 Jan 2018

U.S. judge tosses verdict against AbbVie in AndroGel case

A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

22 Dec 2017

UPDATE 3-U.S. judge tosses verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

22 Dec 2017

CORRECTED-UPDATE 1-U.S. judge tosses verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

22 Dec 2017

U.S. judge tosses $150 mln verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc in the first federal court case to go to trial over claims that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

22 Dec 2017

BRIEF-AbbVie's Upadacitinib Shows Positive Results As Monotherapy In Phase 3 Rheumatoid Arthritis Study

* ABBVIE'S UPADACITINIB SHOWS POSITIVE RESULTS AS MONOTHERAPY IN PHASE 3 RHEUMATOID ARTHRITIS STUDY, MEETING ALL PRIMARY AND KEY SECONDARY ENDPOINTS

20 Dec 2017

BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint

* IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB PHASE 3 INNOVATE TRIAL IN RARE WALDENSTRÖM'S MACROGLOBULINEMIA MET PRIMARY ENDPOINT

05 Dec 2017

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

30 Nov 2017

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

21 Nov 2017

Roche, AbbVie leukemia drug superior to older medicine in study

Nov 21 Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

21 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.36 +0.44
Pfizer Inc. (PFE.N) $36.94 -0.05
Novartis AG (NOVN.S) CHF83.38 +0.48
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Abbott Laboratories (ABT.N) $59.31 +0.24
Eli Lilly and Co (LLY.N) $85.49 -0.33
Sanofi SA (SASY.PA) €72.95 +0.58

Earnings vs. Estimates